InMed Pharmaceuticals Inc. announced that following the launch of INM-901 in October 2023, the next stages of longer-term preclinical studies are
underway in a robust preclinical disease model and will be followed by studies of drug distribution, metabolism (elimination of the drug from the body), pharmacokinetics (how the body interacts with the administered drug) and continuation of pharmaceutical drug development activities such as
manufacturing and formulation. Based on early in vitro research, INM-901 showed potential to target several biological pathways associated with Alzheimer's, including neuroprotection of the brain neurons from beta-amyloid peptide- induced toxicity, a reduction in neuroinflammation and targeting neuronal function improvement via extension of neurite length. In addition to these encouraging in vitro testing outcomes, INM-901 demonstrated favorable results in an in vivo preclinical Alzheimer's proof-of-concept model. When compared to the placebo treated Alzheimer's disease group in these preclinical studies, INM-901 treatment groups demonstrated a trend towards improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness. INM-089 in the treatment of AMD: The Company is currently engaged in API and drug product formulation work and expects to initiate Investigational New Drug ("IND")-enabling studies in mid-2024, with the anticipation of filing an IND application with regulatory authorities in calendar first half of 2025. INM-089 preclinical research has shown promising results in preserving retinal function, proactively protecting retinal cells, and enhancing the thickness of the outer nuclear layer of the retina where photoreceptors are located. INM-755: Assessing partnership opportunities: The comprehensive data and findings from the Phase 2 clinical trial will soon be available on the National Institutes of Health ("NIH") clinicaltrials.gov website and the European Union Clinical Trials Register website. Additionally, an abstract will soon be published in Itch, the official journal of the International Forum for the Study of Itch. The Company believes that INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments. The Company is currently seeking partnerships for continued development.